8:01 AM ET
8-K
Business Update
Filana Therapeutics Business Update
The FDA has lifted a full clinical hold on Filana Therapeutics' IND application for simufilam, allowing the company to proceed with a Phase 2a proof-of-concept study in TSC-related epilepsy. The company expects to begin patient screening by Q1 2027 and has already completed trial-readiness activities including site identification and drug supply preparation.
- Counterparty
- FDA